Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TaiGen Biopharmaceuticals Holdings's share price is NT$8.48.
TaiGen Biopharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.36. Hence, TaiGen Biopharmaceuticals Holdings's PS Ratio for today is 23.30.
Good Sign:
TaiGen Biopharmaceuticals Holdings Ltd stock PS Ratio (=23.29) is close to 3-year low of 22.53.
During the past 13 years, TaiGen Biopharmaceuticals Holdings's highest 3-Year average Revenue per Share Growth Rate was 253.10% per year. The lowest was -65.00% per year. And the median was 22.10% per year.
Back to Basics: PS Ratio
TaiGen Biopharmaceuticals Holdings (ROCO:4157) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
TaiGen Biopharmaceuticals Holdings PS Ratio Related Terms
TaiGen Biopharmaceuticals Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4157 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's PS Ratio falls into.
TaiGen Biopharmaceuticals Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TaiGen Biopharmaceuticals Holdings's Share Price of today is NT$8.48. TaiGen Biopharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a PS Ratio of 23.30 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. This is 82% below median its historical median of 132.28. Over the past decade, TaiGen Biopharmaceuticals Holdings' PS Ratio has ranged from 7.37 to 1,106.25. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #648 out of 930 companies in the Biotechnology industry, placing it in the top 69.7%.
Is TaiGen Biopharmaceuticals Holdings' PS Ratio too high?
TaiGen Biopharmaceuticals Holdings' current PS Ratio of 23.30 is 82% below median its 10-year median of 132.28. Over the past 10 years, this metric has ranged from a low of 7.37 to a high of 1,106.25. The Biotechnology industry median PS Ratio is 9.22. TaiGen Biopharmaceuticals Holdings' value of 23.30 is 152.7% above this industry median. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #648 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #648 out of 930 companies for PS Ratio. This places TaiGen Biopharmaceuticals Holdings in the lower half of its industry. The industry median PS Ratio is 9.22. TaiGen Biopharmaceuticals Holdings' value of 23.30 is 152.7% above this benchmark. Historically, TaiGen Biopharmaceuticals Holdings' own PS Ratio has ranged from 7.37 to 1,106.25 over the past decade. While the company's 10-year median is 132.28 vs. the industry median of 9.22, TaiGen Biopharmaceuticals Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiGen Biopharmaceuticals Holdings's current PS Ratio of 23.30 is 152.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiGen Biopharmaceuticals Holdings's current PS Ratio is 23.30, which is 82% below median its own 10-year median of 132.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.27, compared to a current price of NT$8.48 — trading 75.3% below its estimated fair value. The current PS Ratio is 23.30, which is 82% below median its 10-year median of 132.28 and 152.7% above the Biotechnology industry median of 9.22. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current PS Ratio is 23.30 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.48 is trading 75.3% below its estimated GF Value™ of NT$34.27.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
PS Ratio: 23.30 (82% below median its 10-year median of 132.28)
GF Value™: NT$34.27 vs. price of NT$8.48 (75.3% below fair value)
Industry Position: 152.7% above the Biotechnology median (#648 of 930)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
